AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

TruSpine Technologies Plc

Regulatory Filings Oct 31, 2022

10307_rns_2022-10-31_e3a5a046-cb3f-4fde-b775-ee66b89ee8e0.html

Regulatory Filings

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 7584E

TruSpine Technologies PLC

31 October 2022

TruSpine Technologies plc

("TruSpine" or the "Company")

Update

TruSpine Technologies plc (AQSE: TSP), the medical device company focused on the development of its pioneering "screwless," spinal (vertebral) stabilisation systems announces that the Company has been approached with an equity funding package which would provide the Company with additional working capital.  The board is consulting with its advisers on the proposal and a further announcement will be made in due course.

Further to the announcement of 30 September 2022, the Company's financial position remains weak and the Company has been urgently seeking alternative sources of finance as it is important that additional funding is secured in the near term in order to allow the Company to continue operating. The Company continues to carefully manage its working capital position.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Enquiries:

Truspine Technologies Plc Tel: +44 (0)20 3638 5025
Ian Roberts, CEO
Cairn Financial Advisers LLP (AQSE Corporate Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Ludovico Lazzaretti
Oberon Capital (Joint Broker) Tel: +44 (0)20 3179 5300
Mike Seabrook / Chris Crawford
Peterhouse Capital Limited (Joint Broker & Financial Adviser)

Lucy Williams / Duncan Vasey
Tel: +44 (0)20 7469 0930
Walbrook PR (Financial PR & IR) Tel: +44 (0) 20 7933 7870 or +44 (0) 7876 741 001
Anna Dunphy [email protected]

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXFFLFXLBLXFBX

Talk to a Data Expert

Have a question? We'll get back to you promptly.